Ishida Kota, Shimizu Risa, Endo Iwao, Miyamoto Shingo, Kawakami Kazuyoshi
Dept. of Pharmacy, Japanese Red Cross MedicalCenter.
Gan To Kagaku Ryoho. 2016 Jul;43(7):875-8.
Denosumab is a monoclonal antibody that can be administrated subcutaneously. Although it is not recommended to adjust the dosages for patients with impaired renal function, hypocalcemia has been reported in patients with renal impairment; therefore, it should be administered cautiously. We retrospectively investigated the serum concentrations of calcium after denosumab administration. The results indicated that after continuous administration to patients with a Ccr<40mL/min, serum calcium levels decreased. Grade 2 or above hypocalcemia was detected in 75% of the patients studied. From these results, it is recommended that serum concentrations of calcium be closely monitored in continuous administration of denosu- mab to patients with renal impairment.
地诺单抗是一种可皮下注射的单克隆抗体。虽然不建议对肾功能受损的患者调整剂量，但已有肾功能损害患者出现低钙血症的报道；因此，应谨慎给药。我们回顾性研究了地诺单抗给药后的血清钙浓度。结果表明，在持续给予肌酐清除率（Ccr）<40mL/min的患者后，血清钙水平下降。在75%的研究患者中检测到2级或以上的低钙血症。根据这些结果，建议在对肾功能损害患者持续给予地诺单抗时密切监测血清钙浓度。
Zotero 插件